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Propionic acidemia (PA) is a recessive disorder caused by a deficiency of propionyl-CoA carboxylase (PCC), a dodecameric enzyme
composed of two different proteins a-PCC and h-PCC, nuclear encoded by the PCCA and PCCB genes, respectively. Mutations in either
gene cause PA and to date, up to 47 different allelic variations in the PCCB gene have been identified in different populations. In this work,
we describe the expression studies of 18 PCCB sequence changes in order to elucidate their functional consequences. We have used a PCCB-
deficient transformed fibroblast cell line to target the wild-type and mutant proteins to their physiological situation, analysing the effect of the
mutations on PCC activity and protein stability. Of the 18 mutant proteins tested for activity, those carrying the L17M and A497V
substitutions showed an activity similar to the wild-type one, which proves that these changes do not have any effect on protein activity. The
other 16 mutant proteins exhibited two different functional behaviours, 3 retained substantial activity (K218R, R410W and N536D), and the
remaining 13 proteins showed null or very low activity. Western blot analysis demonstrated instability only for the L519P, R512C and G112D
mutant proteins. We have proved the pathogenicity of R67S, R165Q and G112D mutation in PCCB gene, expressed for the first time in this
work. The information derived from the expression analysis is discussed in the phenotype and genotype context in order to improve the
knowledge of this complex disease.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Propionyl-CoA carboxylase; Propionic acidemia; SV40-transformed skin human fibroblast; Expression study; Phenotype–genotype correlation1. Introduction
Propionic acidemia (PA; MIM 606054) is a life-threat-
ening inborn error of propionate metabolism, which usually
presents in the neonatal period with vomiting, metabolic
acidosis, persistent ketotic episodes, hypotonia, hyperammo-
nemia and neurological symptoms. It is caused by a defi-
ciency of propionyl-CoA carboxylase (PCC; E.C.6.4.1.3),
which is ubiquitously distributed in various tissues and
catalyses the conversion of propionyl-CoA to D-methylma-0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00039-5
$ PCCA-OMIM:232000, 606054 (PA); PCCA gene: GenBank acces-
sion numbers AY035786 to AY035808; cDNA GenBank accession number
AF385926. PCCB-OMIM: 232050, 606054 (PA); PCCB gene: GenBank
accession numbers AJ006487 to AJ006499; cDNA GenBank accession
number X73424. PropionylCoACarboxylase Page: www.uchs.edu/sm/cbs/
pcc/pccmain.htm.
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E-mail address: mugarte@cbm.uam.es (M. Ugarte).lonyl CoA, the major degradation pathway of propionyl-
CoA formed by the catabolism of the essential amino acids
threonine, methionine, valine and isoleucine, odd-chain fatty
acids and cholesterol or gut bacteria [1]. Native PCC is a
heteropolymeric, biotin-dependent mitochondrial enzyme,
composed by two types of subunits, a and h, nuclear
encoded by genes PCCA (MIM 232000) mapping on chro-
mosome 13q32, and PCCB (MIM 232050) mapping on
chromosome 3q13.3-q2, respectively [2,3]. Genomic struc-
tures of both PCCA [4] and PCCB genes [5] are available
and up to date, over 60 mutations have been reported causing
PA [6].
The PCCB gene comprises 15 exons of 57–183 bp in
size. More than half of the mutations identified in the PCCB
gene are missense substitutions and single amino acid
deletions [6–9]. The preferential location of these mutations
in the first exons and, specially, in the last encoding regions
of the gene, may be related to the presence of discrete
functional domains [10,11]. Different expression systems
have been used for the purpose of demonstrating that theseed.
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assembly and/or activity of the PCC enzyme leading to
disease. A chaperone-assisted bacterial expression system
was employed to investigate the primary defect of T428I, a
prevalent PCCB mutation in Japan [12], the A513-R514insP
mutation, prevalent among the Inuit population of Greenland
[8], seven carboxy-terminal mutations of the h-PCC protein
[13], and recently, a number of mutations localized in exons
1, 3–7 and 12–14 [14]. Otherwise, a mammalian two-hybrid
expression system has been used to analyse the molecular
effect on the a–h heteromeric and h–h homomeric assem-
bly of different mutations located at the amino- and carboxy-
terminal regions of the PCCB gene [15,16].
The aim of our work has been to gain further insight on
the functional effect of 18 PCCB sequence changes, most of
them located in regions and residues highly conserved in
orthologous PCCB proteins from different eukaryotic and
prokaryotic species. We have focused our attention on these
common mutations in PA patients from whom we have
thorough biochemical and clinical data, in order to inves-
tigate the genotype–phenotype correlations. With this pur-
pose, we have generated an SV40-transformed fibroblast cell
line from a patient with a defect in the PCCB gene, which
permits the analysis of the expression of normal and mutant
cDNAs, targeting the precursor proteins to the mitochondria,
resembling the in vivo situation better than previously
reported expression analysis. We have recently used this
approach successfully to investigate the effect of 11 different
mutations in the PCCA gene [17]. The information obtained
on activity and stability of the mutant PCCB proteins
expressed in this study is evaluated in the phenotype–
genotype context.2. Methods
2.1. Transformation of a PCCB-deficient cell line
An mRNA-minus skin fibroblasts cell line (MRA) [18],
homozygous for the 1218del14ins12 mutation in the PCCB
gene, which results in a premature stop codon, was stably
transformed using a plasmid (T22) containing SV40 DNA
sequences (courtesy of Dr. P.H. Gallimore, University of
Birmingham, UK) by lipofection as previously described
[19]. After 3 weeks, a phenotypically transformed colony
was selected. Transformed cells were expanded and used in
the transfection experiments.
2.2. Preparation of expression vectors
Expression vectors pCMVA45-12 and pRcCMVB52,
which code for the PCCA and PCCB cDNAs, respectively,
were kindly provided by Dr. Leclerc and Prof. Gravel from
McGill University, Montreal and University of Calgary,
Alberta, Canada, respectively. Vectors containing mutations
were prepared by PCR mutagenesis using the Quickchangemutagenesis kit (Stratagene). The presence of the mutations
in each mutant PCC expression vector was verified by DNA
sequencing on an automated DNA sequencer (ALF Express,
Pharmacia).
2.3. Transient expression of wild-type and mutant PCCB
proteins in the transformed PCCB-deficient cell line
All transfections were carried out by lipofection using
Gene Porterk as transfection reagent. Cells were plated
(0.5 106) onto 25 cm2 cultured flasks and transfected with
40 Al of lipid and a mixture of DNA containing 2 Ag of both
wild-type PCCA and PCCB cDNAs, or 2 Ag of wild-type
PCCA and 2 Ag of mutated PCCB cDNAs in a total of 1.5 ml
Optimem (GIBCO). Two micrograms of pRc/CMV-hgal, the
vector containing E. coli h-galactosidase cDNA, was co-
transfected as an internal control of transfection efficiency.
After 5 h of incubation, the medium was replaced by MEM
with 10% fetal calf serum (FCS) and antibiotics. The trans-
fected cells were harvested with trypsin 72 h after trans-
fection, washed twice with PBS and stored at  80 jC until
use.
2.4. Enzyme assay and protein measurement
PCC activity was determined in fibroblasts extracts
according to Ref. [18]. h-Galactosidase activity was meas-
ured as reported in Ref. [20]. Protein was measured by the
method of Lowry et al. [21].
2.5. b-PCC subunits and b-mRNAs analysis
For the detection of h-PCC protein, mitochondria were
isolated from transfected fibroblasts. The fibroblasts were
harvested by trypsinization, resuspended in sucrose buffer
(0.25 M sucrose, 10 mM Tris–HCl pH 7.4, EDTA 2 mM,
PMSF 0.2 mM), disrupted with a Teflon Potter homogenizer
and differentially centrifuged at 4 jC [22]. The mitochon-
drial pellet was resuspended in sucrose buffer and protein
concentration determined by the Bradford assay. Equal
amounts of total proteins (75 Ag) from each sample were
loaded on a denaturing 9% polyacrylamide gel. After electro-
phoresis, proteins were transferred to nitrocellulose mem-
branes (ProtranR, Schleicher and Schuell). h-PCC protein
was detected using affinity-purified anti-h-PCC obtained
from immunized rabbits as primary antibodies as previously
reported [23].
Total mRNA was isolated using SV total RNA Isolation
Kit (Promega, Madison) from transfected fibroblasts. North-
ern blot analysis was carried out according to standard
procedures [20] using 20 Ag of total RNA transferred to
nylon membranes (GeneScreen Plus, Dupont). The a- and h-
subunits cDNAs extracted from pCMVA45-12 and
pRCCMVB52 were used as probes and radiolabeled with
32P-dCTP using the Random Primer Kit (Stratagene). The
nylon membrane was hybridized with h-PCC probe and
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in each lane.Fig. 1. Western blot analysis of transformed PCCB-deficient cell line (lane
C) transfected with wild-type PCCB cDNA (lane WT) and mutant PCCB
cDNAs. In all cases, PCCA cDNA was co-transfected. Equal amounts of
total protein (75 Ag) from each sample were loaded on a denaturing 9%
polyacrylamide gel and h-PCC subunits were detected using affinity
purified anti-h-PCC subunit as described in Methods.3. Results
3.1. Transient expression experiments
A PCCB-deficient skin fibroblasts cell line homozygous
for a functional null-mutation which does not give rise to any
significant amounts of mRNA or protein was chosen to be
stably transformed. A severely deficient PCC activity in the
clonally transformed cell line ( < 40 pmol/min/mg protein)
confirms that there were no detectable changes resulting from
transformation. In all the expression experiments performed,
the transfection efficiency was monitored by co-expression
of pRc/CMVh-gal, which varied from 1.9 to 4.2 (2.95F 0.8)
O.D./mg protein. The results on PCC activity shown in Table
1 were normalized with respect to the reporter gene activity.
The co-expression of both wild-type PCCA and PCCBTable 1
Analysis of PCC activity in transformed PCCB-deficient fibroblasts
transfected with either wild-type or mutant PCCB cDNA vectors
Transfected cDNA vectorsa PCC activity/
h-galactosidase
activityb
PCC activity
(%)c
pRc/CMV 6.3F 1.3
PCMV/PCCB 86F 8.8
PCMV/PCCA+pCMV/PCCB 2681F 413 100
PCMV/PCCA+pCMV/PCCB
with mutations:
A497V 2954F 485 110
L17M 2690F 128 100
N536D 2158F 234 80
K218R 1881F 274 70
R410W 309F 100 11.5
L519P 36.0F 16.3 1.3
R67S 32.8F 8.1 1.2
E168K 30.8F 3.5 1.1
R512C 30.7F 1.5 1.1
V205D 28.6F 10.3 1.1
W531X 25.7F 10.9 0.95
R44P 23.9F 12.3 0.89
R165W 19.8F 7.3 0.73
R165Q 16.7F 3.1 0.62
G131R 13.3F 3.2 0.49
S106R 10.4F 8.1 0.38
G112D 9.5F 2.1 0.35
G198D N.D. 0
K218R+A497V 1931F 205 72
R165Q+A497V 5.9F 1.3 0.22
The data show the meanF S.D. of duplicate determinations from at least
two independent experiments.
N.D., not detectable. The control-transformed fibroblasts PCC activity is
840F 210 pmol/min/mg protein.
a pRcCMV/h-gal vector was co-transfected in all cases.
b PCC activity values have been normalized taking into account the h-
galactosidase activity obtained for each experiment.
c Residual activity relative to that obtained with co-transfection with
wild-type PCCB and PCCA cDNAs.cDNAs accounted for a higher restoration of enzyme activity
compared with the expression of the wild-type PCCB cDNA
alone. For this reason, the 18 PCCB point substitutions under
study were co-transfected with wild-type PCCA cDNA. The
PCC activity values obtained in each case were compared to
those obtained when wild-type PCCA and PCCB vectors
were co-transfected. The A497V substitution in exon 14,
which has been previously described as a polymorphism
[16], and L17M, which is located in the leader peptide,
resulted in an enzyme activity very close to that found after
expression of the wild-type PCCA and PCCB cDNAs.
Another group of mutations, N536D, K218R and R410W
showed significant degrees of detectable PCC activity and
finally, most of the studied mutations L519P, R67S, E168K,
R512C, V205D, W531X, R44P, R165W, R165Q, G131R,
S106R, G112D and G198D showed close to undetectable
residual PCC activity. Mutant proteins carrying R165Q plus
A497V and K218R plus A497V substitutions were also
assayed, as both R165Q and K218R were always found in
combination with A497V. The double mutants showed close
to undetectable and high residual PCC activity, respectively,
as was expected, taking into account that the A497V variant
allele does not affect PCC activity.
3.2. a- and b-subunit analysis
After isolation of mitochondria from the transfected
fibroblasts, we have analysed the effect of the missense
mutations on the stability of the PCCB protein by Western
blot analysis (Fig. 1). The results showed that most muta-
tions studied produced similar amounts of h-PCC subunit
compared to that produced when wild-type PCCA and PCCB
vectors were transfected, except for G112D which showed
slightly reduced amount and for R512C and L519P muta-
Fig. 2. Northern blot analysis of transformed PCCB-deficient cell line
transfected with wild-type PCCB cDNA (lane WT) and some mutant PCCB
cDNAs. In all cases PCCA cDNA was co-transfected. RNA samples were
separated by electrophoresis through formaldehyde/agarose gel, transferred
to nylon membranes and hybridised with h and a probes, panels A and B,
respectively.
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reduced amount of these variant PCCB proteins is not the
result of different transfection efficiencies as was demon-
strated by similar results of the reporter gene activity for each
experiment. Western blot analysis was also performed in the
clonally transformed PCCB-deficient cell line in order to
confirm the absence of PCCB protein. To discriminate if the
decrease in the amount of expressed protein in mutantsFig. 3. Interspecific alignment of part of the PCCB subunit from different organism
www2.ebi.ac.uk/clustalw). The figure shows the conservation of the mutated re
accession No. P05166), with PCCB from pig (S. scrofa, accession No. P79384), r
AAB54030) and bacteria (B. subtilis, accession No. P54541). The grey schema ind
each alignment column: black (>3), grey (1.5–3) and light grey (0.5–1.5). The sL519P, R512C and G112D is caused by a decreased tran-
scriptional rate, we have performed Northern blot analysis
resulting in normal h-mRNA amount for each mutant cDNA
tested (Fig. 2, panel A). As deduced by the a-PCC probe
hybridisation assay (Fig. 2, panel B), the reduced amount of
L519P h-mRNA should be due to a lower total mRNA
amount loaded in gel. We have included N536D mutation as
control of normal PCCB protein level.
3.3. Alignment analysis
The 18 sequence changes analysed are not randomly
distributed across the gene, most mutations are located in
residues and even in regions highly conserved of the protein
(Fig. 3). The residues affected by mutations R67S, G112D,
G131R, R165Q/W, E168K, G198D, V205D, R410W,
A497V, R512C, L519P and N536D are conserved in all
homologous proteins studied, even among distantly related
species (C. elegans, and B. subtilis), suggesting that these
positions are critical for proper protein function. With the
exception of K218R, the mutant amino acid has never been
observed among species, and the positions vary only in the
invertebrate sequences analysed. L17M, R44P and S106R
substitutions affect residues not conserved in all species.
These variable positions suggest sites where residue changes
can be tolerated by natural selection. The W531X mutations using CLUSTALW software and viewed with the Belvu program (http://
sidues after amino acid alignment of human PCCB subunit (H. sapiens,
at (R. norvegicus, accession No. P07633), worm (C. elegans, accession No.
icates average BLOSUM62 score (correlated to amino acid conservation) in
equences are named with SwissPrott and TrEMBL identifications.
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variable grades of conservation.4. Discussion
After the identification of mutations affecting human
genes the growing interest is to perform the functional
analysis of amino acid allelic variants. The original goal of
this study was to evaluate the effect of several PCCB
missense variations in a eukaryotic expression system that
targets the protein to the mitochondrion, resembling the in
vivo situation more closely. In this way, we have used a
SV40-transformed fibroblast line from a PA patient with an
mRNA minus PCCB mutation to analyse the transient
expression of 18-point sequence changes in order to examineTable 2
Genotype, biochemical data and main clinical manifestation in PA patients bearin
Patient Genotype h-PCC in skin
fibroblasts
PCC activity in
skin fibroblasts (%)
On
dis
AML (L17M+790–791insG)/
E168K
yesa 2.4 lat
AJA R44P/Ins.Del yesa < 1 ear
ASF R67S/R165Q+A497V yesa 1.7 lat
CJF S106R/K218Rb +A497V N.S. 1.2c ear
PVD G131R/Ins.Del yesa 2.3 ear
14763 G112D/A402fs no N.R. ear
12296 R165W/Ins.Del yesa 3 lat
17094 R165Q+A497V/R165Q+
A497V
yes 1 lat
VMP R165Q+A497V/Ins.Del yesa 5 ear
PRG E168K/E168K yesa 1.7 ear
NPU E168K/Ins.Del yesa 3 ear
JGG E168K/Ins.Del yesa 1.5 lat
LGA E168K/Ins.Del yesa 1.2 lat
RSC E168K/Ins.Del yesa < 1 lat
BLWG E168K/1170insT yesa 1.1 lat
MBG E168K/IVS1nt3 + g! c yesa < 1 lat
CTG G198D/G198D N.S. 1.1 ear
EE V205D/V205D yesa < 1 ear
IV V205D/V205D yesa 1.1 lat
TV V205D/V205D yesa < 1 lat
SVL K218Rb +A497V/R165Q+
A497V
yesa 1.3 ear
OVE R410W/IVS10–11del6 yesd 11 lat
HM R410W/E331X yesd 1.2 ?
EAC R512C/Ins.Del no 5 ear
PHG L519P/1170insT no < 1 ear
AG W531X/Ins.Del yesd < 1 ear
500 (534) N536D/Ins.Del yesd 6 lat
17766 N536D/N536D N.S. 14c ?
N.S., not studied; N.R., not reported; early, presentation within 3 weeks of age; l
Reference numbers indicate the articles where patients were previously referred.
a Two bands of h-PCC of normal and reduced size.
b This change produces an in-frame deletion in the mRNA denoted as V217K
c PCC activity determined in lymphocytes.
d h-PCC smaller than normal size.the effect of each change on PCC activity and protein
stability. We have first demonstrated that the PCC defect
can be partially complemented by transfecting the PCCB-
deficient transformed cells with normal PCCB cDNA, as
already reported for primary cultured cells [24]. We have co-
expressed both PCCA and PCCB cDNAs to get optimum
conditions for the production of a functional PCC, i.e. high
activity to be able to detect low residual activity levels. Over-
expression of a- and h-subunit may be necessary for the
overall assembly of the PCC complex in a stoichiometric
manner in order to be functional [17]. We have selected 18
sequences changes found in PA patients from whom we have
thorough biochemical and clinical data (Table 2). With
respect to the observed residual PCC activity after transient
expression, mutations could be classified as having high
(A497Vand L17M), medium (N536D, K218R and R410W)g mutations expressed in this work
set of
ease
Clinical evolution of disease
e Alive 6 years. Psychomotor delay, severe hypotonia, dystonia [7]
ly Alive 13 years. Moderate psychomotor delay, partial epilepsia [18]
e Alive 4 years. Moderate psychomotor delay, ataxia [18]
ly Died 4 months [18]
ly Died 1.5 months [18]
ly [30]
e Alive 10 years. Severe psychomotor delay
e Alive 1 year. Good psychomotor development
ly Alive 14 years. Moderate psychomotor delay, myocardiopathy,
retarded puberal development [18]
ly Alive 6 years. Normal development [18]
ly Alive 14 years. Mild psychomotor delay, myocardiopathy [18]
e Died 26 years [18]
e Alive 12 years. Moderate psychomotor delay, autism [18]
e Died 16 months [18]
e Alive 5 years. Moderate psychomotor delay, partial epilepsia [18]
e Alive 20 years. Moderate psychomotor delay, retarded puberal
development [18]
ly Died 9 months [31]
ly Alive 11 years. Mild psychomotor delay [32]
e Alive 15 years. Normal development, cardiac disease [32]
e Alive 11 years. Mild psychomotor delay, epilepsy with
infections [32]
ly Alive 17 years. Mild psychomotor delay [18]
e Died 5 years [27]
?
ly Died 3 years [18]
ly Alive 7 years. Normal development, mild hypotonia
ly Died 15 days [18]
e Mild [11,33]
Mild
ate, presentation at/after 2 months of age.
218del2 (652A!G).
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R44P. R165W/Q, G131R, S106R, G112D and G198D). The
pathogenicity of R67S, R165Q and G112D mutations, not
yet tested in other expression systems, is therefore con-
firmed. Western blot analysis of the transfected cell line
demonstrated a reduced amount of h-PCC protein only for
L519P, R512C and G112D. The normal h-mRNA amount
found confirms that the decrease in the expressed protein in
mutant L519P, R512C and G112D is caused by loss of
protein stability and not by a decreased transcriptional rate.
Northern and Western blot results are in accordance with
those found in fibroblasts of homozygous and hemizygous
patients carrying the expressed mutations [5].
The A497V and L17M variations, both occurring never
alone, have no effect on PCC activity. We have previously
reported that A497V is a single nucleotide polymorphism
(SNP) showing a low frequency (2%) in control population
[16]. The R165Q and K218R mutations were always found
in association with this SNP in seven chromosomes of five
PCCB-deficient patients from a central region of Spain
(Table 2), indicating that these mutations arose from that
background. Transient expression of the double mutants
A497V + R165Q and A497V + K218R confirmed that
A497V does not have any measurable effect on the mutant
protein. The L17M mutation was identified on the same
chromosome as the frameshift mutation 790–791insG
(Table 2), and produces a near normal PCC activity, as
was expected as this residue is located in the leader peptide
of the h-subunit and is absent in the mature protein.
Three mutations retained substantial activity (N536D,
K218R and R410W). Transient expression of the carboxy-
terminal N536D substitution on the SV40-transformed fibro-
blasts line produced a stable protein by Western blot analysis
with high residual PCC activity, in apparent contradiction
with the impairment found on h–h homomeric assembly in
the mammalian two-hybrid expression system [16] and the
completely degraded mutant protein detected in the E. coli
system [13]. Our analysis revealed that N536D may have a
mild effect on PCC activity, in agreement with the in vivo
situation. We have studied several homozygous patients for
N536D mutation, one of them is reported in Table 2,
showing an unusually high PCC activity in lymphocytes
and a very mild PA phenotype. The change c653A>G
(K218R) is located in the last codon of exon six and we
have recently reported that it affects the normal splicing of
the PCCB gene producing a probably non-functional protein
lacking two amino acids [9]. We cannot rule out the existence
of normal size transcript bearing the K218R missense
variation which we have shown in this study that retains
high PCC activity and thus may contribute to the relatively
mild evolution of the disease in case SVL (Table 2).
Expression of the complementing mutation R410W [25]
produced normal amounts of a h-PCC subunit which is
assembled with a-PCC resulting in a significant reduction
of PCC activity (11.5%), confirming its pathogenic effect,
previously unclear as deduced from the prokaryotic expres-sion analysis [14]. The clinical effect of this mutation is
difficult to assess because there is no clinical information of
the homozygous patient reported by Tahara et al. [26]. We
have reported patient OVE (Table 2) who carries the R410W
substitution in one allele that could produce a partially func-
tional protein that may contribute to his unusual PA disease.
Although this patient was classified as a severe form because
he died after a metabolic stroke at 5 years, he had a
completely unremarkable medical history until the fatal crisis
occurred [27].
The rest of the single-residue substitutions are deleterious
mutations, resulting in a null or nearly null enzyme activity,
suggesting that these residues are important for PCC func-
tion. Three of these mutations, G112D, R512C and L519P
showed a severe effect resulting in an unstable h-subunit
which leads to a nearly undetectable PCC activity, as was also
found in skin fibroblasts of hemizygous patients (Table 2).
Studies on h–h homomeric and/or a–h heteromeric inter-
action [16] and with the chaperone-assisted E. coli expression
system [13] have previously addressed the severity of muta-
tions L519P and R512C that affect the assembly and function
of PCC. The newly expressed mutation G112D may be also
severe but the lack of information on the evolution of the
disease precludes a significant analysis regarding its clinical
effect. In contradiction with previous results in the bacterial
expression system [14], in our hands V205D mutation
produces a stable but catalytically inactive PCC protein, as
also observed in fibroblasts of homozygous patients from two
unrelated Austrian families (Table 2). They all presented
clinically with a late and mild form of PA, suggesting that
other factors such as an increased flow through secondary
pathways preventing propionic acid and its toxic derivatives
from accumulation are probably also determining the devel-
opment of the PA phenotype. Most of the remaining
expressed mutations are located in the amino-terminal region
of the protein. They could also be considered temperature-
sensitive mutations affecting folding and/or function of the
PCC protein as we have shown in previous studies of the
heteromeric and homomeric assembly by a mammalian two-
hybrid expression system [15,16]. For instance, E168K
mutation which is well-represented in patient material (Table
2) results in a broad spectrum of clinical manifestations. This
is expected for folding mutations as the capacity of the
cellular folding and degradation machinery may vary in
different individuals contributing to the variation in the
residual enzyme activity and thus, to the clinical expression
of the disease in different metabolic situations [28,29].
In conclusion, the mammalian expression system we have
designed has proved to be valuable in the interpretation of
many of the mutations causing PA and also efficient to prove
the pathogenicity of newly uncovered missense mutations in
patients. Future crystallization studies of the PCC enzyme
may add valuable information to that achieved by different
expression studies, as demonstrated for the a-PCC subunit,
where most of the missense mutations expressed mapped
closely in the available 3-D structure of the homologous
C. Pe´rez-Cerda´ et al. / Biochimica et Biophysica Acta 1638 (2003) 43–49 49bacterial biotin carboxylase domain, clearly defining a
region probably important for function and/or stability of
the protein [17]. All the results taken together will improve
the understanding of the effect of each amino acid substitu-
tion on enzyme structure and/or function and their relation-
ship to disease phenotype.Acknowledgements
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